dihydralazine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihypertensives, hydrazinephthalazine derivatives	884	484-23-1

Description:

Molecule

Description

Molfile Inchi Smiles

Synonyms:

dihydralazine
dihydralazin
dihydrazinophthalazine
hypopresol
nepresol
nepresolin
nepressol
ophthazin
tonolysin
dihydralazine sulfate
dihydrallazine

1,4-Dihydrazinophthalazine. An antihypertensive agent with actions and uses similar to those of HYDRALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p354)

Molecular weight: 190.21
Formula: C8H10N6
CLOGP: -1.52
LIPINSKI: 0
HAC: 6
HDO: 4
TPSA: 100.82
ALOGS: -2.30
ROTB: 0

Drug dosage:

Dose	Unit	Route
75	mg	O
25	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Hosey CM, Chan R, Benet LZ

Approvals:

None

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Patent ductus arteriosus	94.27	57.23	17	357	4233	63484415
Language disorder	63.56	57.23	11	363	2149	63486499
Premature baby	62.47	57.23	16	358	20719	63467929

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shone complex	105.96	81.60	13	561	72	34956285
Ventricular septal defect	100.56	81.60	21	553	3980	34952377
Patent ductus arteriosus	92.40	81.60	19	555	3335	34953022
Atrial septal defect	87.73	81.60	21	553	7371	34948986

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Product prescribing error	98.73	49.51	30	726	44783	79698849
Language disorder	53.89	49.51	11	745	3203	79740429
Product monitoring error	52.67	49.51	13	743	8893	79734739
Shone complex	52.67	49.51	6	750	30	79743602
Mitral valve hypoplasia	52.67	49.51	6	750	30	79743602
Congenital aortic valve stenosis	52.51	49.51	6	750	31	79743601
Aorta hypoplasia	52.35	49.51	6	750	32	79743600
Congenital heart valve disorder	51.20	49.51	6	750	40	79743592

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C02DB01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON Hydrazinophthalazine derivatives
ATC	C02LG01	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Hydrazinophthalazine derivatives and diuretics
ATC	C02LG51	CARDIOVASCULAR SYSTEM ANTIHYPERTENSIVES ANTIHYPERTENSIVES AND DIURETICS IN COMBINATION Hydrazinophthalazine derivatives and diuretics
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D014665	Vasodilator Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.51	Basic
pKa2	9.9	Basic
pKa3	4.95	Basic
pKa4	4.35	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
N0000167108	NUI
D07170	KEGG_DRUG
235959	RXNORM
C0012271	UMLSCUI
CHEBI:134841	CHEBI
CHEMBL35505	ChEMBL_ID
DB12945	DRUGBANK_ID
D004078	MESH_DESCRIPTOR_UI
10230	PUBCHEM_CID
245	INN_ID
7327-87-9	SECONDARY_CAS_RN
PCU411F5L6	UNII
004347	NDDF
004348	NDDF
703113001	SNOMEDCT_US
703114007	SNOMEDCT_US
D006830	MESH_DESCRIPTOR_UI
CHEMBL2106266	ChEMBL_ID

Pharmaceutical products:

None